Arena Pharmaceuticals Inc
ARNA
ARNA was delisted on the 10th of March, 2022.
160 hedge funds and large institutions have $1.85B invested in Arena Pharmaceuticals Inc in 2018 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 51 increasing their positions, 55 reducing their positions, and 28 closing their positions.
5% more capital invested
Capital invested by funds: $1.75B → $1.85B (+$92.6M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 55
10% less call options, than puts
Call options by funds: $18.6M | Put options by funds: $20.5M
3% less funds holding
Funds holding: 165 → 160 (-5)
14% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$62.1M |
| 2 |
Primecap Management
Pasadena,
California
|
+$40.1M |
| 3 |
PA
Perceptive Advisors
New York
|
+$21.3M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$14.6M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$6.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$65.2M |
| 2 |
PC
PointState Capital
New York
|
-$19.5M |
| 3 |
DM
Deerfield Management
New York
|
-$17.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.6M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$13.5M |
ARNA Hedge Fund Activity: Q3 2018 in Review
160 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q3 2018, worth a combined $1.85B — up 5.3% from $1.75B a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ARNA and 24 opened new positions — a net loss of 4 holders — while 55 trimmed existing stakes and 51 added.
The largest buyer was PFM Health Sciences, adding an estimated $62.1M. The largest seller was Fidelity Investments, cutting an estimated $65.2M.
- 160 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q3 2018, down from 165 in Q2 2018.
- Funds reported $1.85B of Arena Pharmaceuticals Inc stock for Q3 2018, up 5.3% quarter-over-quarter.
- 24 funds opened new Arena Pharmaceuticals Inc positions in Q3 2018 and 28 closed out, a net change of -4 holders.
- The largest Arena Pharmaceuticals Inc buyer in Q3 2018 was PFM Health Sciences, an estimated $62.1M added.
- The largest Arena Pharmaceuticals Inc seller in Q3 2018 was Fidelity Investments, an estimated $65.2M sold.
Based on aggregated 13F filings for Q3 2018.